Medications

Spironolactone noninferior in Duchenne muscular dystrophy

(HealthDay)—In a head-to-head study of mineralocorticoid receptor antagonists, spironolactone was found to be noninferior to eplerenone for slowing the progression of heart damage in boys with Duchenne muscular dystrophy ...

Medical research

Research discovers inhibitor to reverse toxic DUX4 effects

About one in 8,000 people have facioscapulohumeral muscular dystrophy, according to a 2014 study, which is relatively common in the world of genetic diseases. New University of Minnesota Medical School research identifies ...

Medical research

New analysis shows drug slows down respiratory decline

Duchenne muscular dystrophy occurs in boys and is characterized by progressive muscle degeneration and weakness leading to a decline in respiratory function. Strategies to arrest this severe progressive deterioration are ...

page 9 from 34